目的 研究不同剂量重组人生长激素(rhGH)治疗小于胎龄儿(SGA)矮小症的效果和安全性。方法 收集SGA 矮小症患儿37 例,并根据使用剂量分为2 组:小剂量(每日0.1~0.15 IU/kg)rhGH 治疗组和大剂量rhGH 治疗组(每日0.16~0.2 IU/kg),比较两组患儿治疗后3、6、9、12 及24 个月时身高标准差的增长值(ΔHtSDS)、生长速率(HV)、血清胰岛素样生长因子-1(IGF-1)、胰岛素样生长因子结合蛋白-3(IGFBP-3)水平及空腹血糖等指标的变化。结果 大、小剂量rhGH 治疗后ΔHtSDS 及HV 均有提高,但大剂量组治疗后9、12 及24 个月时ΔHtSDS 及HV 均高于小剂量组(P<0.05)。大剂量和小剂量的rhGH 治疗均使血清IGF-1 和IGFBP-3 水平提高,且血清IGF-1 和IGFBP-3 水平与HtSDS 呈正相关。大小剂量组各有1 例患儿出现一过性空腹血糖轻微升高(均为6.1 mmol/L);两组甲状腺功能均无异常。结论 rhGH 治疗SGA 矮小症效果确切,不良反应少,其中大剂量较小剂量治疗更具优势。
Abstract
Objective To investigate the efficacy and safety of different doses of recombinant human growth hormone (rhGH) in the treatment of short stature in children born small for gestational age (SGA). Methods A total of 37 children with short stature born SGA were enrolled, and based on the dose of rhGH treatment, they were divided into low-dose rhGH group (0.1-0.15 IU/kg daily) and high-dose rhGH group (0.16-0.2 IU/kg daily). The changes in height standard deviation score (ΔHtSDS), height velocity (HV), serum levels of insulin-like growth factor-1 (IGF-1) and insulin-like growth factor binding protein-3 (IGFBP-3), and fasting blood glucose at 3, 6, 9, 12, and 24 months after treatment were compared between the two groups. Results ΔHtSDS and HV both increased after the treatment with high-and low-dose rhGH, but ΔHtSDS and HV in the high-dose rhGH group were significantly higher than in the lowdose rhGH group 9, 12 and 24 months after treatment (P<0.05). Both high-and low-dose rhGH treatment increased serum levels of IGF-1 and IGFBP-3. Serum levels of IGF-1 and IGFBP-3 were positively correlated with HtSDS in both groups. One child each in the high-and low-dose rhGH groups experienced transient slight increase in fasting blood glucose (6.1 mmol/L). There were no cases of abnormal thyroid function. Conclusions rhGH has good efficacy in the treatment of short stature in children born SGA, with few adverse events, and high-dose rhGH has some advantages over low-dose rhGH.
关键词
重组人生长激素 /
生长速率 /
治疗剂量 /
小于胎龄儿 /
儿童
Key words
Recombinant human growth hormone /
Height velocity /
Therapeutic dose /
Small for gestational age /
Child
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] Jancevska A, Tasic V, Damcevski N, et al. Children born small for gestational age (SGA) [J]. Prilozi, 2012, 33(2): 47-58.
[2] 中华医学会儿科学分会新生儿学组. 我国小于胎龄儿现状分 析[J]. 中国实用儿科杂志, 2009, 24(3): 177-180.
[3] De Zegher F, Hokken Koelega A. Growth hormone therapy for children born small for gestational age: high gain is less dose dependent over the long term than over the short term[J]. Pediatrics, 2005, 115(4): e458-462.
[4] 中华医学会儿科学分会内分泌遗传代谢学组; 《中华儿科杂 志》编辑委员会．基因重组人生长激素儿科临床规范应用 的建议[J]. 中华儿科杂志, 2013, 51(6): 426-432.
[5] Henwood MJ, Grimberg A, Moshang T Jr. Expanded spectrum of recombinant human growth hormone therapy[J]. Curr Opin Pediatr, 2002, 14(4): 437-442.
[6] 李辉, 季成叶, 宗心南, 等. 中 国0~18 岁儿童、青少年身高、体重的标准化生长曲线[J]. 中华儿科杂志, 2009, 47(7): 487-492.
[7] Hokken-Koelega A, van Pareren Y, Arends N. Effects of growth hormone treatment on cognitive function and head circumference in children born small for gestational age[J]. Horm Res, 2005, 64(Suppl 3): S95-S99.
[8] 中华医学会儿科学分会内分泌遗传代谢学组. 矮身材儿童诊 治指南[J]. 中华儿科杂志, 2008, 46(6): 428-430.
[9] de Zegher F, Albertsson-Wikland K, Wollmann HA, et al. Growth hormone treatment of short children born small for gestational age: growth responses with continuous and discontinuous regimens over 6 years[J]. J Clin Endocrinol Metab, 2000, 85(8): 2816-2821.
[10] Van Pareren Y, Mulder P, Houdijk M, et al. Adult height after long-term, continuous growth hormone (GH) treatment in short children born small for gestational age: results of a randomized, double-blind, dose-response GH trial[J]. J Clin Endocrinol Metab, 2003, 88(8): 3584-3590.
[11] Maiorana A, Cianfarani S. Impact of growth hormone therapy on adult height of children born small for gestational age[J]. Pediatrics, 2009,124(3): e519-e531.
[12] Carel JC, Chatelain P, Rochiccioli P, et al. Improvement in adult height after growth hormone treatment in adolescents with short stature born small for gestational age: results of a randomized controlled study[J]. J Clin Endocrinol Metab, 2003, 88(4): 1587-1593.
[13] van Dijk M1, Bannink EM, van Pareren YK, et al. Risk factors for diabetes mellitus type 2 and metabolic syndrome are comparable for previously growth hormone-treated young adults born small for gestational age (sga) and untreated short SGA controls[J]. J Clin Endocrinol Metab, 2007, 92(1): 160-165.
[14] Sas T, Mulder P, Hokken-Koelega A. Body composition, blood pressure, and lipid metabolism before and during longterm growth hormone (GH) treatment in children with short stature born small for gestational age either with or without GH deficiency[J]. J Clin Endocrinol Metab, 2000, 85(10): 3786-3792.
[15] Saenger P, Reiter E. Genetic factors associated with small for gestational age birth and the use of human growth hormone in treating the disorder [J/OL]. Int J Pediatr Endocrinol, 2012, 2012(1): 12.
[16] Klammt J, Kiess W, Pfäffle R. IGF-1R mutations as cause of SGA[J]. Best Pract Res Clin Endocrinol Metab, 2011, 25(1): 191-206.
[17] Leal Ade C, Canton AP, Montenegro LR, et al. Mutations in insulin-like growth factor receptor 1 gene (IGF-1R) resulting in intrauterine and postnatal growth retardation[J]. Arq Bras Endocrinol Metabol, 2011, 55(8): 541-549.
[18] Trivin C, Souberbielle JC, Aubertin G, et a1. Diagnosis of idiopathic growth hormone deficiency: contributions of data on the acid-labile subunit, insulin-like growth factor (IGF)-I and -II, and IGF binding protein-3[J]. J Pediatr Endocrinol Metab, 2006, 19(4): 481-489.
[19] 吴洁, 毛萌. 小于胎龄儿与胰岛素抵抗的研究进展[J]. 实用 儿科临床杂志, 2006, 21(2): 117-119.
[20] Hales CN, Desai M, Ozanne SE. The thrifty phenotype hypothesis: how does it look after 5 years?[J]. Diabet Med, 1997, 14(3): 189-195.
[21] Bell J, Parker KL, Swinford RD, et a1. Long-term safety of recombinant human growth hormone in children[J]. J Clin Endocrinol Metab, 2010, 95(1): 167-177.
PDF(1789 KB)
